Myriad Genetics Stock

Myriad Genetics Current Assets

The Current Assets of Myriad Genetics (MYGN) as of Aug 7, 2026 is 332.60 M USD. In the previous year, Current Assets was 298.00 M USD — a change of 11.61% (higher).

Current Assets

332.60 MUSD

YoY

11.61%

Last updated:

Current Assets of Myriad Genetics is 2026 332.60 M USD. Current Assets of Myriad Genetics was 2025 298.00 M USD. It decreases by 11.61% higher compared to the previous year.
Access this data via the Eulerpool API

Myriad Genetics Stock analysis

What does Myriad Genetics do? Myriad Genetics Inc. is a biotechnology company specializing in the research of cancer and genetic analysis technologies. The company was founded in 1991 by Mark Skolnick and has since become a global leader in personalized medicine and diagnostics. It is headquartered in Salt Lake City, Utah, USA, and employs over 2,400 employees worldwide. Myriad Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myriad Genetics stock

Current Assets of Myriad Genetics is 332.60 M USD in 2026.

Current Assets of Myriad Genetics changed from 298.00 M USD to 332.60 M USD, representing a 11.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Myriad Genetics since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Myriad Genetics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Myriad Genetics

All Key Metrics — Myriad Genetics